BioStock: New DexTech chairman wants to turn up the volume

With positive phase II data in castration-resistant prostate cancer and upcoming studies in multiple myeloma, DexTech is now taking further steps to accelerate development. Joining the company as the new Chairman of the Board, Andreas Segerros is tasked with building a team to fully leverage the platform technology. BioStock spoke to Segerros to find out more about his background and his view of the mission at DexTech.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/04/new-dextech-chairman-wants-to-turn-up-the-volume/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se